[Pharmacological and clinical profile of lansoprazole (Takepron IV injection 30 mg)]

Nihon Yakurigaku Zasshi. 2008 Feb;131(2):149-56. doi: 10.1254/fpj.131.149.
[Article in Japanese]
No abstract available

Publication types

  • Review

MeSH terms

  • 2-Pyridinylmethylsulfinylbenzimidazoles / pharmacology*
  • 2-Pyridinylmethylsulfinylbenzimidazoles / therapeutic use*
  • Animals
  • Anti-Ulcer Agents / pharmacology*
  • Anti-Ulcer Agents / therapeutic use*
  • Gastric Acid / physiology
  • Gastric Mucosa / drug effects
  • Gastrointestinal Hemorrhage / drug therapy
  • Humans
  • Lansoprazole
  • Peptic Ulcer Hemorrhage / drug therapy

Substances

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Anti-Ulcer Agents
  • Lansoprazole